ClinicalTrials.gg
RecruitingNCT07654361Updated Aug 10, 2026

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

A Phase 3 interventional study of Aleniglipron and Placebo in Obesity, Overweight and Chronic Weight Management, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Recruiting at 71 sites in United States. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics (part of Structure Therapeutics) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,600
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calorie diet and increased physical activity. All participants will be randomized to at least 76 weeks of treatment to evaluate the effects on long term body weight changes, tolerability, and safety. In addition, the study will compare the effects between aleniglipron and placebo on blood pressure (BP), lipid parameters, patient-reported outcomes.

02

Conditions studied

  • Obesity
  • Overweight
  • Chronic Weight Management

Keywords

  • Obesity
  • Overweight
  • GSBR-1290
  • Aleniglipron
  • Chronic weight management
  • Obese
  • Small molecule
  • GLP-1
  • Structure Therapeutics
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's planned enrollment of 3,600 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • ≥30 kg/m2 (obese) or BMI ≥27 kg/m2 (overweight) and presence of ≥1 of the obesity related comorbidities.

Exclusion criteria

Exclusion Criteria:

  • Previously documented diagnosis of type 1 diabetes, type 2 diabetes, or any other type of diabetes.
  • Self-reported change in body weight >5 kg within 3 months before Screening.
  • Have prior or planned surgical or non-surgical treatment for obesity.
  • Have or plan to have endoscopic and/or device-based therapy for obesity.
  • Have obesity induced by other endocrine disorders.
  • Impaired renal function at Screening
  • Chronic malabsorption
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
3,600 participants (estimated)

Study arms

  • Experimental
    aleniglipron Arm 1

    Participants will receive aleniglipron administered orally.

    Drug: Aleniglipron

  • Experimental
    aleniglipron Arm 2

    Participants will receive aleniglipron administered orally.

    Drug: Aleniglipron

  • Experimental
    aleniglipron Arm 3

    Participants will receive aleniglipron administered orally.

    Drug: Aleniglipron

  • Experimental
    Placebo Arm 4

    Participants will receive placebo administered orally.

    Drug: Placebo

Interventions

  • Drug: aleniglipron administered orally Drug

  • DrugPlacebo

    Drug: placebo administered orally

06

What researchers measure

Primary outcomes

  1. Percent change in body weight from Baseline

    Time frame: Baseline and Week 76

Secondary outcomes

  1. Change in body weight (absolute) from Baseline

    Time frame: Baseline and week 76

  2. Percentage of participants who achieve ≥5% reduction in body weight

    Time frame: Baseline and week 76

  3. Percentage of participants who achieve ≥10% reduction in body weight

    Time frame: Baseline and week 76

  4. Percentage of participants who achieve ≥15% reduction in body weight

    Time frame: Baseline and week 76

  5. Percentage of participants who achieve ≥20% reduction in body weight

    Time frame: Baseline and week 76

  6. Change in waist circumference from Baseline

    Time frame: Baseline and week 76

  7. Change in resting systolic blood pressure from Baseline

    Time frame: Baseline and week 76

  8. Percent change in fasting triglycerides and non-HDL cholesterol from Baseline

    Time frame: Baseline and week 76

  9. Change in Impact of Weight on Quality of Life-Lite Clinical Trials Version physical function from Baseline

    Time frame: Baseline and week 76

  10. Change in HbA1c from Baseline

    Time frame: Baseline and week 76

  11. Change in body mass index from Baseline

    Time frame: Baseline and week 76

  12. Percent change in fasting total cholesterol from Baseline

    Time frame: Baseline and week 76

  13. Change in fasting glucose from Baseline

    Time frame: Baseline and week 76

  14. Change in resting diastolic blood pressure from Baseline

    Time frame: Baseline and week 76

Other outcomes

  1. Percentage of participants who achieve ≥25% reduction in body weight

    Time frame: Baseline and week 76

07

Study locations

13 of 71 sites recruiting
  • ACCOMPLISH-1 Research Site
    Birmingham, Alabama 35242, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Birmingham, Alabama 35294-3360, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Phoenix, Arizona 85225, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Sun City West, Arizona 85375, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Tucson, Arizona 85741, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Escondido, California 92025, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Gardena, California 92708, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    La Jolla, California 92108, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Modesto, California 95355, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Rolling Hills Estates, California 90274, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    San Diego, California 92123, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Clearwater, Florida 33756, United States
    Recruiting
  • ACCOMPLISH-1 Research Site
    Leesburg, Florida 34748, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Miami, Florida 33136, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Ocala, Florida 34470, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Ocoee, Florida 34761, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Pembroke, Florida 33027, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Tampa, Florida 33617, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Buford, Georgia 30046, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Columbus, Georgia 31904, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Lawrenceville, Georgia 30046, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Union City, Georgia 30291, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Woodstock, Georgia 30189, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Honolulu, Hawaii 96814-4526, United States
    Recruiting
  • ACCOMPLISH-1 Research Site
    Meridian, Idaho 83646, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Rexburg, Idaho 83440, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Chicago, Illinois 60637, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Iowa City, Iowa 52242, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Wichita, Kansas 67218, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Louisville, Kentucky 40213, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Baton Rouge, Louisiana 70808, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Silver Spring, Maryland 20901-4402, United States
    Recruiting
  • ACCOMPLISH-1 Research Site
    Methuen, Massachusetts 01844, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Needham, Massachusetts 02492, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Ann Arbor, Michigan 48105-1912, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Mankato, Minnesota 56001, United States
    Recruiting
  • ACCOMPLISH-1 Research Site
    Richfield, Minnesota 55423, United States
    Recruiting
  • ACCOMPLISH-1 Research Site
    Gulfport, Mississippi 39503, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Ridgeland, Mississippi 39157, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Chesterfield, Missouri 63005, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Hazelwood, Missouri 63042, United States
    Recruiting
  • ACCOMPLISH-1 Research Site
    St Louis, Missouri 63303-3041, United States
    Recruiting
  • ACCOMPLISH-1 Research Site
    Butte, Montana 59701, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Missoula, Montana 59804, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Omaha, Nebraska 68198-7400, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Las Vegas, Nevada 89128, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Albany, New York 12208-3473, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Brooklyn, New York 11220, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Charlotte, North Carolina 28210, United States
    Recruiting
  • ACCOMPLISH-1 Research Site
    Durham, North Carolina 27710-3000, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Fayetteville, North Carolina 28304, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    New Bern, North Carolina 28562, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Wilmington, North Carolina 28401, United States
    Recruiting
  • ACCOMPLISH-1 Research Site
    Winston-Salem, North Carolina 27104, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Columbus, Ohio 43213, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Columbus, Ohio 43215, United States
    Recruiting
  • ACCOMPLISH-1 Research Site
    Moore, Oklahoma 73160, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Portland, Oregon 97202, United States
    Recruiting
  • ACCOMPLISH-1 Research Site
    Philadelphia, Pennsylvania 19152, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Greer, South Carolina 29651, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Knoxville, Tennessee 37920, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Austin, Texas 78704, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Austin, Texas 78731, United States
    Recruiting
  • ACCOMPLISH-1 Research Site
    Denison, Texas 75020-4582, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Houston, Texas 77040, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Houston, Texas 77054, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    San Antonio, Texas 78231, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Wylie, Texas 75098, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Sandy City, Utah 84094, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    St. George, Utah 84790, United States
    Not yet recruiting
  • ACCOMPLISH-1 Research Site
    Renton, Washington 98057, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address a specific research question in an approved data sharing request

Supporting information: Study protocol

Time frame: Data sharing requests will be considered beginning 36 months after the study publication (manuscript accepted for publication) and either 1) the product has been granted marketing authorization in at least two regulatory jurisdictions, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Researchers will submit a request containing the research objectives, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). Gasherbrum Bio, Inc. does not grant external requests for individual de-identified patient data for the following purposes: Re-evaluating safety and efficacy end points already addressed in the product labelling, Assessing safety or efficacy for an indication in current development Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a panel of external advisors. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Sep 2028, 26 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 26 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2026
First posted
Jun 17, 2026
StartActual
Jul 13, 2026
Primary completionEst.
Sep 2028
CompletionEst.
Nov 2028
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07654361
Responsible party
Sponsor
First posted
Jun 17, 2026
Start date
Jul 13, 2026
Primary completion
Sep 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Aug 10, 2026

Study contacts

Medical Director
Contact
GSBRClinicalTrials@structuretx.com
1-650-457-1959

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aleniglipron

Start the discussion